Appl. No. 10/589,594
Amdt. dated November 21, 2007
Preliminary Amendment for Substitute Sequence Listing

PATENT

Amendments to the Specification:

Please replace the paragraph beginning at page 19, line 27, with the following:

--For example, preferable siRNAs having hairpin structure of the present invention are shown below. In the following structure, the loop sequence can be selected from the group consisting of AUG, CCC, UUCG, CCACC, CTCGAG, AAGCUU, CCACACC, and UUCAAGAGA. Preferable loop sequence is UUCAAGAGA ("ttcaagaga" in DNA). ggagagacugaaaacagag-[B]-cucuguuuucagucucucc (SEQ ID NO:26) (for target sequence of SEQ ID NO:21).--

Please replace the paragraph beginning at page 30, line 33, with the following:

--Total RNA was extracted with a Qiagen RNeasy kit (Qiagen Inc., Valencia, CA, USA) or Trizol reagent (Life Technologies, Inc.) according to the manufacturers' protocols. Ten-microgram aliquots of total RNA were reversely transcribed for single-stranded cDNAs using poly dT_{12-18} primer (SEQ ID NO:27) (SEQ ID NO:26) (Amersham Biosciences Corp., Piscataway, NJ, USA) with Superscript II reverse transcriptase (Life Technologies). Each single-stranded cDNA preparation was diluted for subsequent PCR amplification by standard RT-PCR experiments carried out in 20-μl volumes of PCR buffer (TAKARA). Amplification proceeded for 4 min at 94°C for denaturing, followed by 20 (for *GAPDH*), or 35 (for *C10orf3*) cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 45 s, in the GeneAmp PCR system 9700 (Perkin-Elmer, Foster City, CA). Primer sequences were;

for *GAPDH:* forward, 5'-ACAACAGCCTCAAGATCATCAG-3' (SEQ ID No; 3) and
reverse, 5'-GGTCCACCACTGACACGTTG-3' (SEQ ID No; 4);
for *C10orf3*: forward, 5'- AGAGATCCGAAGAGCTCTTATCT-3' (SEQ ID No; 5) and
reverse: 5'- GATGCTCAGTGGCTGGATACT-3' (SEQ ID No; 6).--

Appl. No. 10/589,594
Amdt. dated November 21, 2007
Preliminary Amendment for Substitute Sequence Listing

PATENT

Please cancel the present Substitute "SEQUENCE LISTING", pages 1-10, submitted June 11, 2007, and insert therefor the accompanying paper copy of the Substitute Sequence Listing, page numbers 1 to 11, at the end of the application.